Skip to main content

Table 1 Baseline demographics and epilepsy characteristics (intent-to-treat population)

From: Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study

  Overall VPA stratum CBZ stratum
  LEV (n = 152) Standard AEDs (n = 155) LEV (n = 48) VPA-ER (n = 52) LEV (n = 104) CBZ-CR (n = 103)
Age, years, mean (SD) 69.5 (6.2) 69.7 (6.4) 71.1 (6.8) 70.4 (6.5) 68.8 (5.9) 69.3 (6.4)
Gender, n (%)
 Men 85 (55.9) 87 (56.1) 25 (52.1) 33 (63.5) 60 (57.7) 54 (52.4)
 Women 67 (44.1) 68 (43.9) 23 (47.9) 19 (36.5) 44 (42.3) 49 (47.6)
Number of seizures in the last 2 yearsa, median (Q1–Q3) [n] 4 (2–6) [150] 4 (2–8) [149] 3 (2–6) [47] 3 (2–5) [51] 4 (2–8) [102] 4 (3–10) [99]
Epilepsy durationb, years, median (Q1–Q3) 0.70
(0.27–2.95)
0.70
(0.30–2.12)
0.79
(0.20–2.24)
0.73
(0.26–1.84)
0.63
(0.28–3.15)
0.70
(0.32–2.55)
Seizure typec, n (%)
 Simple focal 30 (19.7) 32 (20.6) 5 (10.4) 4 (7.7) 25 (24.0) 28 (27.2)
 Complex focal 62 (40.8) 62 (40.0) 15 (31.3) 11 (21.2) 47 (45.2) 51 (49.5)
 SG or tonic clonic 84 (55.3) 89 (57.4) 30 (62.5) 38 (73.1) 54 (51.9) 51 (49.5)
 Otherd 4 (2.6) 4 (2.6) 3 (6.3) 3 (5.8) 1 (1.0) 1 (1.0)
 Unclassifiede 5 (3.3) 3 (1.9) 4 (8.3) 3 (5.8) 1 (1.0) 0
  1. Abbreviations: AED antiepileptic drug, CBZ carbamazepine, CBZ-CR controlled-release carbamazepine, LEV levetiracetam, SG secondarily generalised, VPA sodium valproate, VPA-ER extended-release sodium valproate
  2. aOverall: LEV, n = 149; standard AEDs, n = 150. CBZ stratum: LEV, n = 102; CBZ-CR, n = 99. VPA stratum: LEV, n = 47; VPA-ER, n = 51
  3. bTime since first seizure
  4. cPatients are counted once in each type of seizure experienced
  5. dIncluding absence, myoclonic, clonic, tonic and atonic seizures
  6. eIncluding unclassified, unable to clarify and unknown seizure types